表紙
市場調査レポート

MEI Pharma, Inc.:製品パイプライン分析

MEI Pharma, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 285611
出版日 ページ情報 英文 31 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
MEI Pharma, Inc.:製品パイプライン分析 MEI Pharma, Inc. - Product Pipeline Review - 2015
出版日: 2015年11月18日 ページ情報: 英文 31 Pages
概要

MEI Pharma, Inc.は、癌治療薬の臨床開発を専門とする企業です。

当レポートでは、MEI Pharma, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

MEI Pharma, Inc.の基本情報

MEI Pharma, Inc.の概要

  • 主要情報
  • 企業情報

MEI Pharma, Inc.:R&Dの概要

  • 主な治療範囲

MEI Pharma, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

MEI Pharma, Inc.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

MEI Pharma, Inc.:薬剤プロファイル

  • pracinostat
  • ME-143
  • ME-344
  • NV-128
  • PWT-143
  • SB-1502

MEI Pharma, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

MEI Pharma, Inc.:最近のパイプライン動向

MEI Pharma, Inc.:休止中のプロジェクト

MEI Pharma, Inc.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07707CDB

Summary

Global Markets Direct's, 'MEI Pharma, Inc. - Product Pipeline Review - 2015', provides an overview of the MEI Pharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MEI Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of MEI Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of MEI Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the MEI Pharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate MEI Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of MEI Pharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the MEI Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of MEI Pharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of MEI Pharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of MEI Pharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • MEI Pharma, Inc. Snapshot
    • MEI Pharma, Inc. Overview
    • Key Information
    • Key Facts
  • MEI Pharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • MEI Pharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • MEI Pharma, Inc. - Pipeline Products Glance
    • MEI Pharma, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • MEI Pharma, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • MEI Pharma, Inc. - Drug Profiles
    • pracinostat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ME-344
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PWT-143
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NV-128
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • MEI Pharma, Inc. - Pipeline Analysis
    • MEI Pharma, Inc. - Pipeline Products by Target
    • MEI Pharma, Inc. - Pipeline Products by Route of Administration
    • MEI Pharma, Inc. - Pipeline Products by Molecule Type
    • MEI Pharma, Inc. - Pipeline Products by Mechanism of Action
  • MEI Pharma, Inc. - Recent Pipeline Updates
  • MEI Pharma, Inc. - Dormant Projects
  • MEI Pharma, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • MEI Pharma, Inc., Key Information
  • MEI Pharma, Inc., Key Facts
  • MEI Pharma, Inc. - Pipeline by Indication, 2015
  • MEI Pharma, Inc. - Pipeline by Stage of Development, 2015
  • MEI Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • MEI Pharma, Inc. - Phase II, 2015
  • MEI Pharma, Inc. - Phase I, 2015
  • MEI Pharma, Inc. - Preclinical, 2015
  • MEI Pharma, Inc. - Pipeline by Target, 2015
  • MEI Pharma, Inc. - Pipeline by Route of Administration, 2015
  • MEI Pharma, Inc. - Pipeline by Molecule Type, 2015
  • MEI Pharma, Inc. - Pipeline Products by Mechanism of Action, 2015
  • MEI Pharma, Inc. - Recent Pipeline Updates, 2015
  • MEI Pharma, Inc. - Dormant Developmental Projects,2015

List of Figures

  • MEI Pharma, Inc. - Pipeline by Top 10 Indication, 2015
  • MEI Pharma, Inc. - Pipeline by Stage of Development, 2015
  • MEI Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • MEI Pharma, Inc. - Pipeline by Top 10 Target, 2015
  • MEI Pharma, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • MEI Pharma, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • MEI Pharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top